TBI

Home>Tag:TBI
Feb 8 2024

Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing

By |2024-02-08T08:07:03-05:00February 8th, 2024|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA February 8, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed ...

Nov 15 2023

Halberd Corporation Plans to Extend Research Partnership with Mississippi State University

By |2023-11-14T18:09:30-05:00November 15th, 2023|Featured, Investor News, News, Press Releases|0 Comments

MSU Research for Halberd to Transcend the TBI Nasal Spray Jackson Center, PA November 15, 2023 – Halberd Corporation (OTC-PINK: "HALB”) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent ...

Oct 10 2023

Hartman, CEO and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast

By |2023-10-09T16:58:07-04:00October 10th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, October 10, 2022 – Halberd Corporation (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S. Felder were recently interviewed on “The Street Reports Podcast” to update the public on several of the company’s important projects: The significant results to-date of Halberd’s proprietary nasal spray testing ...

Oct 4 2023

Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)

By |2023-10-03T20:16:16-04:00October 4th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA October 4, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing: 25% reduction in Neuron Specific Enolase ...

Sep 6 2023

Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)

By |2023-09-06T05:46:15-04:00September 6th, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Anecdotal Results of Halberd’s Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers Jackson Center, PA September 6, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd’s patent-pending nasal spray to mitigate ...

Aug 14 2023

Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses

By |2023-08-13T19:31:35-04:00August 14th, 2023|Featured, Investor News, News|0 Comments

Scientific Paper Presented at Research Symposium Jackson Center, PA August 14, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University (MSU). MSU students, Jourdan, L.K., Broadaway, S. Cassen, et. al. authored and presented a paper on this project at the recent Mississippi ...

May 23 2023

Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete

By |2023-05-22T20:43:29-04:00May 23rd, 2023|Featured, Investor News, Press Releases|0 Comments

MSU is ahead of schedule and continues testing program Jackson Center, PA May 23, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray.  The nasal spray is designed to eliminate ...

Apr 11 2023

Halberd Begins Preclinical Testing at Mississippi State University (MSU)

By |2023-04-11T08:01:10-04:00April 11th, 2023|Featured, Investor News, News|0 Comments

Jackson Center, PA April 11, 2023 – Halberd Corporation (OTC-PINK: "HALB”) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI). This innovative research involves the development of test mechanisms by MSU's staff to quantify ...

Mar 30 2023

Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma

By |2023-03-29T19:43:38-04:00March 30th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA March 30, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU.  The testing will focus on Halberd’s patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining ...

Feb 22 2022

Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually

By |2022-02-21T18:59:51-05:00February 22nd, 2022|Featured, Investor News, Medical, News, Press Releases|1 Comment

Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.  With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens.  See Table Below.  This could lead to ...

Go to Top